Radiotherapy for Ovarian Cancers - Redefining the Role |
Rai, Bhavana
(Department of Radiotherapy and Oncology and Regional Cancer Centre, Postgraduate Institute of Medical Education and Research)
Bansal, Anshuma (Department of Radiotherapy and Oncology and Regional Cancer Centre, Postgraduate Institute of Medical Education and Research) Patel, Firuza Darius (Department of Radiotherapy and Oncology and Regional Cancer Centre, Postgraduate Institute of Medical Education and Research) Sharma, Suresh Chander (Department of Radiotherapy and Oncology and Regional Cancer Centre, Postgraduate Institute of Medical Education and Research) |
1 | Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ (2002). Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol, 20, 1248-59. DOI ScienceOn |
2 | Shetty UM, Shankar S, Engineer R, et al (2013). Image guided intensity modulated whole abdomen radiation therapy in relapsed epithelial ovarian cancers: a feasibility study. J Can Res Ther, 9, 17-21. DOI |
3 | Sirichaisutdhikorn D, Suprasert P, Khunamornpong S (2009). Clinical outcome of the ovarian clear cell carcinoma compared to other epithelial ovarian cancers when treated with paclitaxel and carboplatin. Asian Pac J Cancer Prev, 10, 1041-5. |
4 | Sorbe B (2003). Consolidation treatment of advanced (FIGO stage III) ovarian carcinoma in complete surgical remission after induction chemotherapy: a randomized, controlled, clinical trial comparing whole abdominal radiotherapy, chemotherapy, and no further treatment. Int J Gynecol Cancer, 13, 276-8. |
5 | Swenerton KD, Santos JL, Gilks CB, et al (2011). Histotype predicts the curative potential of radiotherapy: The example of ovarian cancers. Ann Oncol, 22, 341-7. DOI ScienceOn |
6 | Thomas G (2013). Revisiting the role of radiation treatment for non-serous subtypes of epithelial ovarian cancer. Am Soc Clin Oncol Educ Book, 31, e205. |
7 | Yahara K, Ohguri T, Imada H, et al (2013). Epithelial ovarian cancer: definitive radiotherapy for limited recurrence after complete remission had been achieved with aggressive front-line therapy. J Radiat Res, 54, 322-9. DOI |
8 | Murthy NS, Shalini S, Suman G, Pruthvish S, Mathew A (2009). Changing trends in incidence of ovarian cancer - the Indian scenario. Asian Pac J Cancer Prev, 10, 1025-30. |
9 | Kobel M, Kalloger SE, Huntsman DG, et al (2010). Differences in tumor type in low-stage versus high-stage ovarian carcinomas. Int J Gynecol Pathol, 29, 203-11. DOI ScienceOn |
10 | Kojs Z, Glinski B, Reinfuss M, et al (2001). Results of a randomized prospective trial comparing postoperative abdominopelvic radiotherapy with postoperative chemotherapy in early ovarian cancer. Cancer Radiother, 5, 5-11. DOI ScienceOn |
11 | Mahantshetty U, Jamema S, Engineer R, et al (2010). Whole abdomen radiation therapy in ovarian cancers: a comparison between fixed beam and volumetric are based intensity modulation. Radiat Oncol, 15, 106. |
12 | Nagai Y, Inamine M, Hirakawa M, et al (2007). Postoperative whole abdominal radiotherapy in clear cell adenocarcinoma of the ovary. Gynecol Oncol, 107, 469-73. DOI ScienceOn |
13 | Ozols RF (1997): Controversies in the management of ovarian cancer. Int J Gynecol Cancer, 7, 27-32. |
14 | Quon M, Gallant V, Samant R (2006). Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer. Gynecol Oncol, 102, 204-9. DOI ScienceOn |
15 | Rochet N, Kieser M, Sterzing F, et al (2011). Phase II study evaluating consolidation whole abdominal intensitymodulated radiotherapy (IMRT) in patients with advanced ovarian cancer stage FIGO III--the OVAR-IMRT-02 Study. BMC Cancer, 28, 11-41. |
16 | De Meerleer G, Vandecasteele K, Ost P, et al (2011). Whole abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative treatment of chemotherapyresistant ovarian cancer with bulky peritoneal disease: a single-institution experience. Int J Radiat Oncol Biol Phys, 79, 775-81. DOI ScienceOn |
17 | Dembo AJ (1992). Epithelial ovarian cancer: the role of radiotherapy. Int J Radiat Oncol Biol Phys, 22, 835-45. DOI |
18 | Brown AP, Jhingran A, Klopp AH, et al(2013). Involved-field radiation therapy for locoregionally recurrent ovarian cancer. Gynecol Oncol, 130, 300-5. DOI ScienceOn |
19 | Chang JS, Koom WS, Kim SW, et al(2013). Risk stratification of abdominopelvic failure for FIGO stage III epithelial ovarian cancer patients: implications for adjuvant radiotherapy. J Gynecol Oncol, 24, 146-53. DOI ScienceOn |
20 | Corn BW, Lanciano RM, Boente M, et al (1994). Recurrent ovarian cancer. Effective radiotherapeutic palliation after chemotherapy failure. Cancer, 74, 2979-83. DOI |
21 | Dembo AJ, Bush RS (1982). Choice of postoperative therapy based on prognostic factors. Int J Radiat Oncol Biol Phys, 8, 893-7. DOI |
22 | Dembo AJ, Bush RS, Beale FA, et al (1979). Improved survival following abdominopelvic irradiation in patients with a completed pelvic operation. Am J Obstet Gynecol, 134, 793-800. DOI |
23 | Eltabbakh GH, Goodrich S (2006). Update on the treatment of recurrent ovarian cancer. Womens Health (Lond Engl), 2, 127-39. DOI ScienceOn |
24 | Gocheva L (2003). Whole abdomen irradiation in epithelial ovarian cancer - state of the art. Wspotczesna Onkologia, 13, 181-90. |
25 | Hoskins PJ, Le N, Gilks B, et al (2012). Low-stage ovarian clear cell carcinoma: population-based outcomes in British Columbia, Canada, with evidence for a survival benefit as a result of irradiation. J Clin Oncol, 30, 1656-62. DOI ScienceOn |
26 | Rochet N, Sterzing F, Jensen AD, et al (2010). Intensitymodulated whole abdominal radiotherapy after surgery and carboplatin/taxane chemotherapy for advanced ovarian cancer: phase I study. Int J Radiat Oncol Biol Phys, 76, 1382-9. DOI ScienceOn |
27 | Bhurgri Y, Shaheen Y, Kayani N, et al (2011). Incidence, trends and morphology of ovarian cancer in Karachi (1995-2002). Asian Pac J Cancer Prev, 12, 1567-71. |
28 | Biete A, Valduvieco I, Rovirosa A, et al (2010). Whole abdominal radiotherapy in ovarian cancer. Rep Pract Oncol Radiother, 15, 27-30. DOI ScienceOn |
29 | Suprasert P, Manopunya M, Cheewakriangkrai C (2014). Outcomes with single agent LIPO-DOX in platinumresistant ovarian and fallopian tube cancers and primary peritoneal adenocarcinoma - Chiang Mai University Hospital Experience. Asian Pac J Cancer Prev, 15, 1145-8. DOI ScienceOn |